20 results on '"Gorbatchevsky I"'
Search Results
2. Phase II study of copanlisib, a PI3K inhibitor, in relapsed or refractory, indolent or aggressive lymphoma
- Author
-
Dreyling, M., Morschhauser, F., Bouabdallah, K., Bron, D., Cunningham, D., Assouline, S. E., Verhoef, G., Linton, K., Thieblemont, C., Vitolo, U., Hiemeyer, F., Giurescu, M., Garcia-Vargas, J., Gorbatchevsky, I., Liu, L., Koechert, K., Peña, C., Neves, M., Childs, B. H., and Zinzani, P. L.
- Published
- 2017
- Full Text
- View/download PDF
3. COASTAL: A PHASE 3 STUDY OF THE PI3Kδ INHIBITOR ZANDELISIB WITH RITUXIMAB (R) VERSUS IMMUNOCHEMOTHERAPY IN PATIENTS WITH RELAPSED INDOLENT NON‐HODGKIN’S LYMPHOMA (INHL)
- Author
-
Jurczak, W., primary, Zinzani, P. L., additional, Cunningham, D., additional, Yavrom, S., additional, Huang, W., additional, Gorbatchevsky, I., additional, and Ribrag, V., additional
- Published
- 2021
- Full Text
- View/download PDF
4. ZANDELISIB, A PI3Kδ INHIBITOR ON INTERMITTENT SCHEDULE (IS) IN FOLLICULAR LYMPHOMA PATIENTS WHO PROGRESSED WITHIN 24 MONTHS OF FIRST‐LINE CHEMOIMUNOTHERAPY (POD24)
- Author
-
Pagel, J., primary, Reddy, N., additional, Jagadeesh, D., additional, Stathis, A., additional, Asch, A. S., additional, Salman, H., additional, Kenkre, V. P., additional, Soumerai, J. D., additional, Llorin‐Sangalang, J., additional, Gorbatchevsky, I., additional, Li, J., additional, and Zelenetz, A. D., additional
- Published
- 2021
- Full Text
- View/download PDF
5. A phase II, multicenter study to evaluate the efficacy and safety using autologous tumor infiltrating lymphocytes (LN-145) in patients with recurrent, metastatic, or persistent cervical carcinoma
- Author
-
Jazaeri, A.A., primary, Edwards, R.P., additional, Zsiros, E., additional, Brown, R.J., additional, Gorbatchevsky, I., additional, Suzuki, S., additional, and Wenham, R.M., additional
- Published
- 2018
- Full Text
- View/download PDF
6. CLINICAL OUTCOMES AND MOLECULAR CHARACTERIZATION FROM a PHASE II STUDY OF COPANLISIB IN PATIENTS WITH RELAPSED OR REFRACTORY DIFFUSE LARGE B-CELL LYMPHOMA
- Author
-
Lenz, G., primary, Hawkes, E., additional, Verhoef, G., additional, Haioun, C., additional, Lim, S., additional, Heo, D., additional, Ardeshna, K., additional, Chong, G., additional, Christensen, J.H., additional, Shi, V., additional, Lippert, S., additional, Hiemeyer, F., additional, Piraino, P., additional, Beckmann, G., additional, Peña, C., additional, Buvaylo, V., additional, Childs, B.H., additional, Gorbatchevsky, I., additional, and Salles, G., additional
- Published
- 2017
- Full Text
- View/download PDF
7. A phase III, randomized, double-blind, placebo-controlled study of erlotinib plus ARQ 197 versus erlotinib plus placebo in previously treated subjects with locally advanced or metastatic, nonsquamous, non-small cell lung cancer (NSCLC) .
- Author
-
Sandler, A., primary, Schiller, J. H., additional, Hirsh, V., additional, Sequist, L. V., additional, Soria, J., additional, Von Pawel, J., additional, Wang, Q., additional, Pande, A. U., additional, Schwartz, B. E., additional, Garmey, E. G., additional, Gorbatchevsky, I., additional, and Scagliotti, G., additional
- Published
- 2011
- Full Text
- View/download PDF
8. Phase I results of the randomized, placebo controlled, phase I/II study of the novel oral c-MET inhibitor, ARQ 197, irinotecan (CPT-11), and cetuximab (C) in patients (pts) with wild-type (WT) KRAS metastatic colorectal cancer (mCRC) who have received front-line systemic therapy.
- Author
-
Bessudo, A., primary, Bendell, J. C., additional, Gabrail, N., additional, Kopp, M. V., additional, Mueller, L., additional, Hart, L. L., additional, Vladimirov, V. I., additional, Pande, A. U., additional, Gorbatchevsky, I., additional, and Eng, C., additional
- Published
- 2011
- Full Text
- View/download PDF
9. A phase II multicenter evaluation of ARQ 197 monotherapy in patients with relapsed or refractory germ cell tumors (GCTs).
- Author
-
Feldman, D. R., primary, Einhorn, L. H., additional, Quinn, D. I., additional, Horwich, A., additional, Loriot, Y., additional, Joffe, J. K., additional, Vaughn, D. J., additional, Flechon, A., additional, Hajdenberg, J., additional, Pande, A. U., additional, Liu, K., additional, Gorbatchevsky, I., additional, and Motzer, R. J., additional
- Published
- 2011
- Full Text
- View/download PDF
10. Phase I results of the randomized, placebo controlled, phase I/II study of the novel oral c-Met inhibitor, ARQ 197, irinotecan (CPT-11), and cetuximab (C) in patients (pts) with wild-type (WT) KRAS metastatic colorectal cancer (mCRC) who have received front-line systemic therapy.
- Author
-
Eng, C., primary, Bendell, J. C., additional, Bessudo, A., additional, Gabrail, N. Y., additional, Diamond, J., additional, Pande, A. U., additional, and Gorbatchevsky, I., additional
- Published
- 2011
- Full Text
- View/download PDF
11. Randomized phase III trial of pixantrone compared with other chemotherapeutic agents for third-line single-agent treatment of relapsed aggressive non-Hodgkin's lymphoma
- Author
-
Pettengell, R., primary, Narayanan, G., additional, Mendoza, F. H., additional, Digumarti, R., additional, Gomez, H., additional, Cernohous, P., additional, and Gorbatchevsky, I., additional
- Published
- 2009
- Full Text
- View/download PDF
12. EXTEND PIX301: a phase III randomized trial of pixantrone versus other chemotherapeutic agents as third-line monotherapy in patients with relapsed, aggressive non-Hodgkin's lymphoma.
- Author
-
Engert A, Herbrecht R, Santoro A, Zinzani PL, and Gorbatchevsky I
- Published
- 2006
13. Pixantrone dimaleate versus other chemotherapeutic agents as a single-agent salvage treatment in patients with relapsed or refractory aggressive non-Hodgkin lymphoma: a phase 3, multicentre, open-label, randomised trial.
- Author
-
Pettengell R, Coiffier B, Narayanan G, de Mendoza FH, Digumarti R, Gomez H, Zinzani PL, Schiller G, Rizzieri D, Boland G, Cernohous P, Wang L, Kuepfer C, Gorbatchevsky I, and Singer JW
- Abstract
BACKGROUND: Pixantrone dimaleate (pixantrone)-a novel aza-anthracenedione-was synthesised to reduce anthracycline-related cardiotoxicity without compromising antitumour efficacy. We aimed to assess the efficacy and safety of pixantrone versus an investigator's choice of a single-agent therapy in heavily pretreated patients with relapsed or refractory aggressive non-Hodgkin lymphoma. METHODS: In this phase 3, multicentre, open-label, randomised trial at 66 hospitals in Europe, India, Russia, South America, the UK, and the USA, patients with histologically confirmed aggressive non-Hodgkin lymphoma who had relapsed after two or more previous chemotherapy regimens were randomly assigned (1:1) by an interactive voice response system to treatment with pixantrone dimaleate (85 mg/m(2) intravenously on days 1, 8, and 15 of a 28-day cycle, for up to six cycles) or to a comparator (vinorelbine, oxaliplatin, ifosfamide, etoposide, mitoxantrone, or gemcitabine) given at prespecified standard doses and schedules. Patients were stratified by region, International Prognostic Index score, and previous stem-cell transplantation. Patients and investigators were not masked to treatment assignment; however, an independent assessment panel was masked. The primary endpoint was the proportion of patients with a complete or unconfirmed complete response in the intention-to-treat (ITT) population at the end of treatment. Primary analyses of efficacy were based on the independent assessment panel's data review. The study is registered at ClinicalTrials.gov, number NCT00088530. FINDINGS: The ITT population comprised 70 patients randomly assigned to the pixantrone group and 70 to the comparator. Five patients (two in the pixantrone group and three in the comparator group) dropped out before receiving their study drug. 14 patients (20·0% [95% CI 11·4-31·3]) who received pixantrone achieved a complete or unconfirmed complete response at end of treatment compared with four patients (5·7% [1·6-14·0]) in the comparator group (p = 0·021). The most common grade 3 or 4 adverse events in patients given pixantrone were uncomplicated, non-cumulative neutropenia (28 [41·2%] of 68 patients vs 13 [19·4%] of 67 patients in the comparator group), leucopenia (16 [23·5%] vs five [7·5%]), and thrombocytopenia (eight [11·8%] vs seven [10·4%]). INTERPRETATION: Pixantrone, given as a single-agent salvage therapy in heavily pretreated patients with relapsed or refractory aggressive non-Hodgkin lymphoma, is efficacious and tolerable. It could be a treatment option for patients whose aggressive non-Hodgkin lymphoma has failed to respond to at least two previous chemotherapy regimens. FUNDING: Cell Therapeutics, Inc. [ABSTRACT FROM AUTHOR]
- Published
- 2012
14. Phase II study of copanlisib, a PI3K inhibitor, in relapsed or refractory, indolent or aggressive lymphoma
- Author
-
Dominique Bron, Catherine Thieblemont, Umberto Vitolo, M Neves, Kim Linton, Martin Dreyling, Igor Gorbatchevsky, Pier Luigi Zinzani, J. Garcia-Vargas, David Cunningham, Li Liu, Carol Peña, Karl Koechert, M. Giurescu, Barrett H. Childs, Sarit Assouline, Krimo Bouabdallah, Gregor Verhoef, Florian Hiemeyer, Franck Morschhauser, Dreyling, M, Morschhauser, F, Bouabdallah, K, Bron, D, Cunningham, D, Assouline, S. E, Verhoef, G, Linton, K, Thieblemont, C, Vitolo, U, Hiemeyer, F, Giurescu, M, Garcia-Vargas, J, Gorbatchevsky, I, Liu, L, Koechert, K, Peña, C, Neves, M, Childs, B. H, Zinzani, P. L., Klinikum der Universität [München], Groupe de Recherche sur les formes Injectables et les Technologies Associées - ULR 7365 (GRITA), Université de Lille-Centre Hospitalier Régional Universitaire [Lille] (CHRU Lille), CHU Bordeaux [Bordeaux], Ecole de Santé Publique [Université Libre de Bruxelles], Université libre de Bruxelles (ULB), IBM Thomas J. Watson Research Center, IBM, Jewish General Hospital, University Hospitals Leuven [Leuven], Manchester University NHS Foundation Trust (MFT), Hopital Saint-Louis [AP-HP] (AP-HP), Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP), Università degli studi di Torino (UNITO), Bayer Pharma AG [Berlin], Bayer HealthCare Pharmaceuticals Inc [Whippany], University of Bologna, Università degli studi di Torino = University of Turin (UNITO), University of Bologna/Università di Bologna, Université de Lille, CHU Lille, Groupe de Recherche sur les formes Injectables et les Technologies Associées (GRITA) - EA 7365, Groupe de Recherche sur les formes Injectables et les Technologies Associées - ULR 7365 [GRITA], Manchester University NHS Foundation Trust [MFT], Hopital Saint-Louis [AP-HP] [AP-HP], and Università degli studi di Torino = University of Turin [UNITO]
- Subjects
Male ,0301 basic medicine ,Pathology ,copanlisib ,Lymphoma ,[SDV]Life Sciences [q-bio] ,Follicular lymphoma ,Phases of clinical research ,Aggressive lymphoma ,Gastroenterology ,Phosphatidylinositol 3-Kinases ,chemistry.chemical_compound ,0302 clinical medicine ,Recurrence ,Phosphoinositide-3 Kinase Inhibitors ,Aged, 80 and over ,Haematologic Malignancies ,Manchester Cancer Research Centre ,treatment ,Lymphoma, Non-Hodgkin ,Malignant lymphoma ,Hematology ,Middle Aged ,Hodgkin Disease ,3. Good health ,Oncology ,030220 oncology & carcinogenesis ,Female ,Rituximab ,malignant lymphoma ,medicine.drug ,medicine.medical_specialty ,Antineoplastic Agents ,PI3K inhibitor ,Neutropenia ,03 medical and health sciences ,Internal medicine ,Biomarkers, Tumor ,medicine ,Humans ,Survival analysis ,Aged ,Copanlisib ,business.industry ,ResearchInstitutes_Networks_Beacons/mcrc ,PTEN Phosphohydrolase ,Original Articles ,medicine.disease ,Isoflavones ,Survival Analysis ,Treatment ,Editor's Choice ,Pyrimidines ,030104 developmental biology ,chemistry ,Quinazolines ,business ,Hématologie - Abstract
Background: Copanlisib is a pan-class I phosphatidylinositol 3-kinase inhibitor with predominant activity against the α- and δ-isoforms. Patients and methods: This phase II study evaluated the response rate of copanlisib administered intravenously on days 1, 8, and 15 of a 28-day cycle, in patients with indolent or aggressive malignant lymphoma. Archival tumor tissues were used for immunohistochemistry, gene-expression profiling, and mutation analysis. Results: Thirty-three patients with indolent lymphoma and 51 with aggressive lymphoma received copanlisib. Follicular lymphoma (48.5%) and peripheral T-cell lymphoma (33.3%) were the most common histologic subtypes. Most patients (78.6%) had received prior rituximab and 54.8% were rituximab-refractory. Median duration of treatment was 23 and 8 weeks in the indolent and aggressive cohorts, respectively (overall range 2-138). Eighty patients were evaluated for efficacy. The objective response rate was 43.7% (14/32) in the indolent cohort and 27.1% (13/48) in the aggressive cohort; median progression-free survival was 294 days (range 0-874) and 70 days (range 0-897), respectively; median duration of response was 390 days (range 0-825) and 166 days (range 0-786), respectively. Common adverse events included hyperglycemia (57.1%; grade ≥3, 23.8%), hypertension (54.8%; grade ≥3, 40.5%), and diarrhea (40.5%; grade ≥3, 4.8%), all generally manageable. Neutropenia occurred in 28.6% of patients (grade 4, 11.9%). Molecular analyses showed enhanced antitumor activity in tumors with upregulated phosphatidylinositol 3-kinase pathway gene expression. Conclusion: Intravenous copanlisib demonstrated promising efficacy and manageable toxicity in heavily pretreated patients with various subtypes of indolent and aggressive malignant lymphoma. Subtype-specific studies of copanlisib in patients with follicular, peripheral T-cell, and mantle cell lymphomas are ongoing., SCOPUS: ar.j, info:eu-repo/semantics/published
- Published
- 2017
15. EXTEND PIX301: A Phase III Randomized Trial of Pixantrone Versus Other Chemotherapeutic Agents as Third-Line Monotherapy in Patients with Relapsed, Aggressive Non-Hodgkin's Lymphoma
- Author
-
Rauol Herbrecht, Pier Luigi Zinzani, Andreas Engert, Armando Santoro, Igor Gorbatchevsky, Engert A, Herbrecht R, Santoro A, Zinzani PL, and Gorbatchevsky I.
- Subjects
Adult ,Male ,Oncology ,Cancer Research ,medicine.medical_specialty ,Adolescent ,Anthracycline ,medicine.medical_treatment ,Antineoplastic Agents ,Pharmacology ,chemistry.chemical_compound ,Internal medicine ,medicine ,Humans ,Aged ,Mitoxantrone ,Chemotherapy ,Pixantrone ,Performance status ,business.industry ,Lymphoma, Non-Hodgkin ,Relapsing Fever ,Combination chemotherapy ,Hematology ,General Medicine ,Middle Aged ,Isoquinolines ,Regimen ,chemistry ,Acute Disease ,Female ,business ,ESHAP ,medicine.drug - Abstract
The standards of care for firstand second-line therapy have been well established in aggressive non-Hodgkin’s lymphoma (NHL).1 Initial therapy includes CHOP (cyclophosphamide/ doxorubicin/vincristine/prednisone) with or without rituximab, which may be followed by an autologous stem cell transplantation procedure in selected patients.2-4 Patients who experience relapse after an initial complete response (CR) or who have refractory disease receive high-dose chemotherapy with a non–crossresistant combination regimen in an attempt to achieve a second response. Active regimens include DHAP (dexamethasone/ cytarabine/cisplatin), ESHAP (methylprednisolone/etoposide/ cytarabine/cisplatin), and ICE (ifosfamide/carboplatin/ etoposide).5-7 Patients responding to second-line therapy might be eligible for consolidation therapy with autologous stem cell transplantation.8 The standard CHOP regimen cures 30%-40% of patients with advanced, aggressive NHL9; of the remaining patients, approximately half will respond to second-line treatment.8 However, no standard therapy has been established for patients experiencing relapse or with refractory disease after second-line treatment. Although initial therapy is intended to be curative, the treatment goal for patients in whom firstand second-line therapy is failing is palliative, and depending on performance status and prognosis, patients may receive single-agent or combination chemotherapy.10 A formal comparison of the clinical benefits of single-agent versus combination therapy in this setting is not available. However, several single agents are reportedly active in patients with second or greater relapse of aggressive NHL, including etoposide, vinorelbine, oxaliplatin, ifosfamide, mitoxantrone, gemcitabine, and rituximab.10-13 Pixantrone is an anthraquinone-based inhibitor of topoisomerase II. It is similar to the anthracycline doxorubicin and the anthracenedione mitoxantrone but lacks the 5,8-dihydroxy–substitution pattern of mitoxantrone that has been implicated in treatment-related cardiac toxicity.14 Preclinical studies showed that the activity of pixantrone against hematologic neoplasias in a mouse model is greater than that of doxorubicin or mitoxantrone.15 In a phase I study in patients with relapsed/refractory malignant lymphoma, pixantrone was well tolerated and showed encouraging antitumor activity in heavily pretreated patients.16 The recommended dose from this study was 84 mg/m2 daily in an once weekly for 3 weeks treatment schedule (days 1, 8, and 15 of a 28-day cycle). The activity of single-agent pixantrone was evaluated in a phase II study predominantly enrolling elderly patients with multiply relapsed, aggressive NHL.17 Thirty-three patients with a median age of 66 years were treated with pixantrone as a single agent at 85 mg/m2 daily on days 1, 8, and 15 of a 28-day cycle. Confirmed responses included 5 CRs and 4 partial remissions, with the median duration of response being > 11 months. The regimen was generally well tolerated, although the third dose in each cycle was frequently delayed or omitted because of myelosuppressive toxicity. The present study is designed to compare the efficacy of single-agent pixantrone to other singleagent treatment options in patients with aggressive NHL who have received 2 combination chemotherapy regimens. EXTEND PIX301: A Phase III Randomized Trial of Pixantrone Versus Other Chemotherapeutic Agents as Third-Line Monotherapy in Patients with Relapsed, Aggressive Non-Hodgkin’s Lymphoma
- Published
- 2006
16. Pixantrone dimaleate versus other chemotherapeutic agents as a single-agent salvage treatment in patients with relapsed or refractory aggressive non-Hodgkin lymphoma: a phase 3, multicentre, open-label, randomised trial
- Author
-
Paul Cernohous, Bertrand Coiffier, Raghunadharao Digumarti, Fernando Hurtado de Mendoza, David A. Rizzieri, Gary J. Schiller, Ruth Pettengell, Jack W. Singer, Geetha Narayanan, Giles W. Boland, Igor Gorbatchevsky, Henry L. Gomez, Lixia Wang, Pier Luigi Zinzani, Christine Kuepfer, Pettengell R, Coiffier B, Narayanan G, de Mendoza FH, Digumarti R, Gomez H, Zinzani P.L., Schiller G, Rizzieri D, Boland G, Cernohous P, Wang L, Kuepfer C, Gorbatchevsky I, and Singer JW.
- Subjects
Adult ,Male ,medicine.medical_specialty ,refractory aggressive non-Hodgkin lymphoma ,Adolescent ,salvage treatment ,Population ,Salvage therapy ,Antineoplastic Agents ,Aggressive Non-Hodgkin Lymphoma ,Vinorelbine ,Ventricular Function, Left ,chemistry.chemical_compound ,International Prognostic Index ,Internal medicine ,medicine ,Humans ,education ,Aged ,Aged, 80 and over ,Salvage Therapy ,education.field_of_study ,Ifosfamide ,Pixantrone ,business.industry ,Pixantrone dimaleate ,Lymphoma, Non-Hodgkin ,Middle Aged ,Isoquinolines ,Surgery ,Transplantation ,Oncology ,chemistry ,Female ,business ,medicine.drug - Abstract
Summary Background Pixantrone dimaleate (pixantrone)—a novel aza-anthracenedione—was synthesised to reduce anthracycline-related cardiotoxicity without compromising antitumour efficacy. We aimed to assess the efficacy and safety of pixantrone versus an investigator's choice of a single-agent therapy in heavily pretreated patients with relapsed or refractory aggressive non-Hodgkin lymphoma. Methods In this phase 3, multicentre, open-label, randomised trial at 66 hospitals in Europe, India, Russia, South America, the UK, and the USA, patients with histologically confirmed aggressive non-Hodgkin lymphoma who had relapsed after two or more previous chemotherapy regimens were randomly assigned (1:1) by an interactive voice response system to treatment with pixantrone dimaleate (85 mg/m 2 intravenously on days 1, 8, and 15 of a 28-day cycle, for up to six cycles) or to a comparator (vinorelbine, oxaliplatin, ifosfamide, etoposide, mitoxantrone, or gemcitabine) given at prespecified standard doses and schedules. Patients were stratified by region, International Prognostic Index score, and previous stem-cell transplantation. Patients and investigators were not masked to treatment assignment; however, an independent assessment panel was masked. The primary endpoint was the proportion of patients with a complete or unconfirmed complete response in the intention-to-treat (ITT) population at the end of treatment. Primary analyses of efficacy were based on the independent assessment panel's data review. The study is registered at ClinicalTrials.gov, number NCT00088530. Findings The ITT population comprised 70 patients randomly assigned to the pixantrone group and 70 to the comparator. Five patients (two in the pixantrone group and three in the comparator group) dropped out before receiving their study drug. 14 patients (20·0% [95% CI 11·4–31·3]) who received pixantrone achieved a complete or unconfirmed complete response at end of treatment compared with four patients (5·7% [1·6–14·0]) in the comparator group (p = 0·021). The most common grade 3 or 4 adverse events in patients given pixantrone were uncomplicated, non-cumulative neutropenia (28 [41·2%] of 68 patients vs 13 [19·4%] of 67 patients in the comparator group), leucopenia (16 [23·5%] vs five [7·5%]), and thrombocytopenia (eight [11·8%] vs seven [10·4%]). Interpretation Pixantrone, given as a single-agent salvage therapy in heavily pretreated patients with relapsed or refractory aggressive non-Hodgkin lymphoma, is efficacious and tolerable. It could be a treatment option for patients whose aggressive non-Hodgkin lymphoma has failed to respond to at least two previous chemotherapy regimens. Funding Cell Therapeutics, Inc.
- Published
- 2012
17. Paediatric strategy forum for medicinal product development of PI3-K, mTOR, AKT and GSK3β inhibitors in children and adolescents with cancer.
- Author
-
Pearson AD, DuBois SG, Macy ME, de Rojas T, Donoghue M, Weiner S, Knoderer H, Bernardi R, Buenger V, Canaud G, Cantley L, Chung J, Fox E, Friend J, Glade-Bender J, Gorbatchevsky I, Gore L, Gupta A, Hawkins DS, Juric D, Lang LA, Leach D, Liaw D, Lesa G, Ligas F, Lindberg G, Lindberg W, Ludwinski D, Marshall L, Mazar A, McDonough J, Nysom K, Ours C, Pappo A, Parsons DW, Rosenfeld A, Scobie N, Smith M, Taylor D, Weigel B, Weinstein A, Karres D, and Vassal G
- Subjects
- Humans, Child, Adolescent, Phosphoinositide-3 Kinase Inhibitors therapeutic use, Phosphoinositide-3 Kinase Inhibitors pharmacology, MTOR Inhibitors therapeutic use, MTOR Inhibitors pharmacology, Protein Kinase Inhibitors therapeutic use, Protein Kinase Inhibitors pharmacology, Antineoplastic Agents therapeutic use, Antineoplastic Agents pharmacology, Signal Transduction drug effects, Neoplasms drug therapy, Neoplasms genetics, Glycogen Synthase Kinase 3 beta antagonists & inhibitors, Glycogen Synthase Kinase 3 beta metabolism, Proto-Oncogene Proteins c-akt antagonists & inhibitors, Proto-Oncogene Proteins c-akt metabolism, TOR Serine-Threonine Kinases antagonists & inhibitors
- Abstract
Phosphatidylinositol 3-kinase (PI3-K) signalling pathway is a crucial path in cancer for cell survival and thus represents an intriguing target for new paediatric anti-cancer drugs. However, the unique clinical toxicities of targeting this pathway (resulting in hyperglycaemia) difficulties combining with chemotherapy, rarity of mutations in childhood tumours and concomitant mutations have resulted in major barriers to clinical translation of these inhibitors in treating both adults and children. Mutations in PIK3CA predict response to PI3-K inhibitors in adult cancers. The same mutations occur in children as in adults, but they are significantly less frequent in paediatrics. In children, high-grade gliomas, especially diffuse midline gliomas (DMG), have the highest incidence of PIK3CA mutations. New mutation-specific PI3-K inhibitors reduce toxicity from on-target PI3-Kα wild-type activity. The mTOR inhibitor everolimus is approved for subependymal giant cell astrocytomas. In paediatric cancers, mTOR inhibitors have been predominantly evaluated by academia, without an overall strategy, in empiric, mutation-agnostic clinical trials with very low response rates to monotherapy. Therefore, future trials of single agent or combination strategies of mTOR inhibitors in childhood cancer should be supported by very strong biological rationale and preclinical data. Further preclinical evaluation of glycogen synthase kinase-3 beta inhibitors is required. Similarly, even where there is an AKT mutation (∼0.1 %), the role of AKT inhibitors in paediatric cancers remains unclear. Patient advocates strongly urged analysing and conserving data from every child participating in a clinical trial. A priority is to evaluate mutation-specific, central nervous system-penetrant PI3-K inhibitors in children with DMG in a rational biological combination. The choice of combination, should be based on the genomic landscape e.g. PTEN loss and resistance mechanisms supported by preclinical data. However, in view of the very rare populations involved, innovative regulatory approaches are needed to generate data for an indication., Competing Interests: Declaration of Competing Interest RB is an employee of Genentech, A Member of the Roche Group, South San Francisco, CA USA. JC is an employee of Bayer Healthcare Pharmaceuticals, Whippany, NJ, USA. SGD has received consulting fees for advisory board participation from Amgen, Bayer, InhibRx, and Jazz and travel funding from Loxo, Roche, and Salarius. JF is an employee of Kazia Therapeutics. IG an employee of Celcuity. HK is an employee of Loxo Oncology at Lilly. DL is an employee of Merck Sharp & Dohme. AM is an employee of Actuate. MEM has receiving consulting fees for advisory board participation from Ymabs Therapeutics, Recordati and travel funding from Bayer. KN has received consulting fees for advisory board participation from Y-mAbs, EUSA Pharma and Bayer, fees for teaching from Bayer and serving on a data monitoring committee from Lilly. ADJP has consulted for Lilly, Norgine and Developmental Therapeutics Consortium Limited and been an advisor for Amgen. All remaining authors have declared no conflicts of interest., (Copyright © 2024 The Authors. Published by Elsevier Ltd.. All rights reserved.)
- Published
- 2024
- Full Text
- View/download PDF
18. Gedatolisib in combination with palbociclib and endocrine therapy in women with hormone receptor-positive, HER2-negative advanced breast cancer: results from the dose expansion groups of an open-label, phase 1b study.
- Author
-
Layman RM, Han HS, Rugo HS, Stringer-Reasor EM, Specht JM, Dees EC, Kabos P, Suzuki S, Mutka SC, Sullivan BF, Gorbatchevsky I, and Wesolowski R
- Subjects
- Female, Humans, Adolescent, Adult, Receptor, ErbB-2 metabolism, Disease-Free Survival, Antineoplastic Combined Chemotherapy Protocols adverse effects, TOR Serine-Threonine Kinases, Breast Neoplasms drug therapy, Breast Neoplasms genetics, Breast Neoplasms metabolism, Morpholines, Piperazines, Pyridines, Triazines
- Abstract
Background: The PI3K-mTOR pathway is frequently dysregulated in breast cancer. Combining an inhibitor targeting all class I PI3K isoforms and mTOR complex 1 (mTORC1)-mTOR complex 2 (mTORC2) with endocrine therapy and a CDK4/6 inhibitor might provide more effective tumour control than standard-of-care therapy. To evaluate this hypothesis, gedatolisib, a pan-PI3K-mTOR inhibitor, was assessed in a phase 1b trial combined with palbociclib and endocrine therapy in patients with hormone receptor-positive, HER2-negative, advanced breast cancer. Results from the dose expansion portion of this trial are reported herein., Methods: This multicentre, open-label, phase 1b study recruited female patients aged at least 18 years from 17 sites across the USA with hormone-receptor-positive, HER2-negative, advanced breast cancer and an Eastern Cooperative Oncology Group performance status of 0-1. Four patient groups were studied in the dose expansion portion of the study: treatment-naive in the advanced setting (first line; group A), progression on 1-2 lines of endocrine therapy but CDK4/6 inhibitor-naive (group B); and one or more previous lines (second-line and higher) of therapy, including a CDK4/6 inhibitor (groups C and D). Gedatolisib 180 mg was administered intravenously weekly in 28-day treatment cycles for groups A-C, and on days 1, 8, and 15 for group D. Letrozole (group A), fulvestrant (groups B-D), and palbociclib (all groups) were administered at standard doses and schedules. The primary endpoint was investigator-assessed objective response rate per RECIST version 1.1 in the evaluable analysis set. This trial is completed and registered with ClinicalTrials.gov, NCT02684032., Findings: Between Dec 19, 2017, and June 19, 2019, 103 female participants were enrolled in the dose expansion groups A (n=31), B (n=13), C (n=32), and D (n=27). Median follow-up was 16·6 months (IQR 5·7-48·4) for group A, 11·0 months (7·6-16·9) for group B, 3·6 months (1·8-7·5) for group C, and 9·4 months (5·3-16·7) for group D for the primary endpoint. Gedatolisib, palbociclib, and endocrine therapy induced an objective response in 23 (85·2%; 90% CI 69·2-94·8) of 27 evaluable first-line participants (group A). In the second-line and higher setting, an objective response was observed in eight (61·5%; 90% CI 35·5-83·4) of 13 evaluable group B participants, seven (25·0%; 12·4-41·9) of 28 evaluable group C participants, and 15 (55·6%; 38·2-72·0) of 27 evaluable group D participants; this included participants with both wild-type and mutated PIK3CA tumours. The most common grade 3-4 treatment-related adverse events were neutropenia (65 [63%] of 103), stomatitis (28 [27%]), and rash (21 [20%]). Grade 3-4 hyperglycaemia was reported in six (6%) participants. 23 (22%) of 103 participants had a treatment-related serious adverse event, and there were no treatment-related deaths. Nine (9%) participants discontinued treatment because of a treatment-emergent adverse event., Interpretation: Gedatolisib plus palbociclib and endocrine therapy showed a promising objective response rate compared with the published results for standard-of-care therapies and had an acceptable safety profile., Funding: Pfizer and Celcuity., Competing Interests: Declaration of interests RML received medical writing support and institutional research funding from Celcuity and Pfizer; institutional research funding from Novartis, Eli Lilly, Puma, Zentalis, Arvinas, and Accutar Biotechnology; and consulting fees from or participation on advisory boards for Celcuity, Pfizer, Novartis, Eli Lilly, Gilead, and Biotheryx. HSH received institutional research funding from Abbvie, Arvinas, Celcuity, Department of Defense, G1 Therapeutics, GlaxoSmith Kline, Horizon Oncology Research, Marker Therapeutics, Mersana, Novartis, Pfizer, Phoenix Pharmaceuticals, Pyonr, QuantumLeap Health, and Seagen, Zymeworks; consulting fees from or participation on advisory boards for Daiichi Sankyo–Astra Zeneca, Immunomedics–Gilead, and Novartis; and Speaker's Bureau fees for Eli Lilly. HSR received institutional research funding from Astellas Pharma, AstraZeneca, Daiichi Sankyo, F Hoffmann-La Roche–Genentech, Gilead Sciences, GlaxoSmithKline, Lilly, Merck, Novartis Pharmaceuticals Corporation, OBI Pharma, Pfizer, Pionyr; consulting fees from or participation on advisory boards for Napo Pharmaceutical, Puma Biotechnology, Blueprint, Scorpion Therapeutics, and Daiichi Sankyo; and honoraria from Blueprint, Mylan, and Puma Biotechnology. EMS-R received research funding from Susan G Komen, V Foundation, NIH, and Breast Cancer Research Foundation; consulting fees from or participation on advisory boards for Lilly, SeaGen, Immunomedics, Tersera, AstraZeneca, Merck, Novartis, and Mylan; other payments or honoraria from the American Society of Clinical Oncology, the National Comprehensive Cancer Network, American Association for Cancer Research–Bristol Myers Squibb–Winn Clinical Trials Workshop. JMS received institutional research funding from Celcuity, Pfizer, Merck, Seagen, Seattle Genetics, Minerva, Myriad Pharmaceuticals, Novartis, Genentech, Cascadian Therapeutics, Abbvie, and Nektar; consulting fees from Volastra and GE Healthcare; royalties or licenses from UW Comotion as a donation to the UW Breast Program; honoraria from Binaytara Foundation, Washington State Medical Oncology Society, and Hong Kong International Oncology Symposium; meeting or travel support from ECOG ACRIN, A2 Biotherapeutics, IwCAR-T, the Society of Nuclear Medicine and Molecular Imaging, and Translational Breast Cancer Research Consortium; and is a member of data safety monitoring or advisory boards for GE Healthcare, Sensei Biotherapeutics, and GlaxoSmithKline. ECD received institutional research funding from Merck, Novartis, Meryx, H3 Biomedicine, and G1 Therapeutics and participated on the data safety monitoring board for Sanofi. PK received institutional research funding from AstraZeneca, Hibercell, Sanofi, Eli Lilly, Zymeworks, and Genentech. SS is a full-time employee of Celcuity receiving a salary and holding shares in Celcuity; and received consulting fees from Celcuity (before employment), Artiva Biotherapeutics, Elevation Oncology, Kartos Therapeutics, Tellios Pharma, and Direct Biologics. SCM, BFS, and IG are full-time employees of Celcuity receiving a salary and holding shares in Celcuity. RW received institutional research funding from Celcuity and Pfizer, is a member of advisory boards for Celcuity and Seagen, and is a member of the investigational steering committee for this study., (Copyright © 2024 Elsevier Ltd. All rights reserved.)
- Published
- 2024
- Full Text
- View/download PDF
19. Correction: Single-agent activity of phosphatidylinositol 3-kinase inhibition with copanlisib in patients with molecularly defined relapsed or refractory diffuse large B-cell lymphoma.
- Author
-
Lenz G, Hawkes E, Verhoef G, Haioun C, Thye Lim S, Seog Heo D, Ardeshna K, Chong G, Haaber J, Shi W, Gorbatchevsky I, Lippert S, Hiemeyer F, Piraino P, Beckmann G, Peña C, Buvaylo V, Childs BH, and Salles G
- Published
- 2024
- Full Text
- View/download PDF
20. Single-agent activity of phosphatidylinositol 3-kinase inhibition with copanlisib in patients with molecularly defined relapsed or refractory diffuse large B-cell lymphoma.
- Author
-
Lenz G, Hawkes E, Verhoef G, Haioun C, Thye Lim S, Seog Heo D, Ardeshna K, Chong G, Haaber J, Shi W, Gorbatchevsky I, Lippert S, Hiemeyer F, Piraino P, Beckmann G, Peña C, Buvaylo V, Childs BH, and Salles G
- Subjects
- Adult, Aged, Aged, 80 and over, CD79 Antigens genetics, Female, High-Throughput Nucleotide Sequencing, Humans, Lymphoma, Large B-Cell, Diffuse genetics, Lymphoma, Large B-Cell, Diffuse mortality, Male, Middle Aged, Mutation, Pyrimidines adverse effects, Quinazolines adverse effects, Recurrence, Lymphoma, Large B-Cell, Diffuse drug therapy, Phosphoinositide-3 Kinase Inhibitors therapeutic use, Pyrimidines therapeutic use, Quinazolines therapeutic use
- Abstract
Patients with relapsed/refractory diffuse large B-cell lymphoma (DLBCL) have adverse outcomes. We evaluated the efficacy and safety of the phosphatidylinositol 3-kinase inhibitor copanlisib in patients with relapsed/refractory DLBCL and assessed the relationship between efficacy and DLBCL cell of origin (COO; activated B-cell like [ABC] and germinal center B-cell like [GCB]) and other biomarkers. The primary endpoint was objective response rate (ORR) in DLBCL COO subgroups (ABC, GCB, and unclassifiable) and by CD79B mutational status (NCT02391116). Sixty-seven patients received copanlisib (ABC DLBCL, n = 19; GCB DLBCL, n = 30; unclassifiable, n = 3; missing, n = 15). The ORR was 19.4%; 31.6% and 13.3% in ABC and GCB DLBCL patients, respectively. ORR was 22.2%/20.0% for patients with/without CD79B mutations (wild type, n = 45; mutant, n = 9; missing, n = 13). Overall median progression-free survival and duration of response were 1.8 and 4.3 months, respectively. Adverse events included hypertension (40.3%), diarrhea (37.3%), and hyperglycemia (32.8%). Aberrations were detected in 338 genes, including BCL2 (53.7%) and MLL2 (53.7%). A 16-gene signature separating responders from nonresponders was identified. Copanlisib treatment demonstrated a manageable safety profile in patients with relapsed/refractory DLBCL and a numerically higher response rate in ABC vs. GCB DLBCL patients.
- Published
- 2020
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.